Company: PFSA
Filing Date: 2025-08-11
Form Type: S-1
Source: 0001213900-25-073872
Chunk: 47

Company: Profusa, Inc.
Filing Date: 2025-08-11
Form: S-1
Chunk 47
---
 funding of life sciences research and development or changes that impact budgets or budget cycles; •the timing of when we recognize any revenues; •future accounting pronouncements or changes in our accounting policies; •the outcome of any future litigation or governmental investigations involving the Company, our industry or both; •higher than anticipated service, replacement and warranty costs; •the impact of the COVID -19pandemic on the economy, investment in the life sciences and medical technology industries, our business operations, and resources and operations of our suppliers, future distributors and current and potential customers; •the impact of political instability and military conflict, such as the conflict in Ukraine, which has resulted in instability in the global financial markets and export controls, and which could result in supply disruptions for us; and •general industry, economic and market conditions and other factors, including factors unrelated to our operating performances or the operating performance of our competitors. The cumulative effects of the factors discussed above could result in large fluctuations and unpredictability in our quarterly and annual operating results. As a result, comparing our operating results on a period -to-periodbasis may not be meaningful. This variability and unpredictability could also result in us failing to meet the expectations of industry or financial analysts or investors for any period. If we are unable to further commercialize products or generate revenue, or if our operating results fall below the expectations of analysts or investors or below any guidance we may provide, or if the guidance we provide is below the expectations of analysts or investors, the market price of our common stock could decline. 28 If our financial performance fails to meet the expectations of investors and public market analysts, the market price of our common stock could decline. Our revenues and operating results may fluctuate significantly from quarter to quarter. We believe that period -to-periodcomparisons of our operating results may not be meaningful and should not be relied on as an indication of our future performance. If quarterly revenues or operating results fall below the expectations of investors or public market analysts, the trading price of our common stock could decline substantially. Factors that might cause quarterly fluctuations in our operating results include: •our inability to manufacture an adequate supply of product at appropriate quality levels and acceptable costs; •possible delays in our research and development programs or in the completion of any clinical trials; •a lack of acceptance of our products in the marketplace; •the inability of customers to receive reimbursements from third -partypayors; •the purchasing patterns of our customers; •failures to comply with regulatory requirements, which could lead to withdrawal